Navigation Links
Fujitsu PalmSecure and HT Systems' PatientSecure Selected by ValleyCare Health System to Protect Patient Records and Comply With New 'Red Flag' Regulations
Date:11/3/2008

Palm Vein Recognition Technology Protects Patient Privacy and Safeguards Electronic Medical Records to Help ValleyCare Comply with Federal Trade Commission's new Identity Theft Regulations

SUNNYVALE, Calif., Nov. 3 /PRNewswire/ -- Fujitsu Computer Products of America, Inc., a leading supplier of innovative computer products including hard disk drives, peripherals and biometric security solutions, today announced that ValleyCare Health System in Pleasanton, Calif. is using the Fujitsu PalmSecure(TM) palm vein authentication technology as part of its new Patient Access Lifetime Match (PALM) patient registration and identification system. ValleyCare is the first hospital in California -- and the third in the U.S. -- to use this solution. PALM is HT Systems' PatientSecure system that integrates PalmSecure with Siemens MedSeries 4 Hospital Information Systems to provide ValleyCare with a highly accurate, non-intrusive verification method for effectively identifying patients. The combined solution protects patient privacy, safeguards Electronic Medical Records (EMRs) and helps ValleyCare comply with the Federal Trade Commission's (FTC) new Identity Theft "Red Flag" regulations by enabling administrators to quickly identify, detect, and respond to medical identity theft.

"Providing the best healthcare possible is the number-one priority at ValleyCare, and we are constantly seeking ways to provide quicker care to our patients while protecting their confidentiality," said Marcy Feit, CEO at ValleyCare. "Integrating Fujitsu PalmSecure and HT Systems' PatientSecure into our new PALM solution enables us to streamline our patient registration and identification processes while ensuring EMRs and patient privacy are protected. PALM also helps us comply with the FTC's new 'Red Flag' regulations by preventing medical fraud and identity theft."

Beginning November 1, 2008, the FTC requires healthcare providers to develop programs to safeguard against identi
'/>"/>

SOURCE Fujitsu Computer Products of America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Image Sensing Systems Announces Third Quarter Financial Results
2. Hill-Rom Announces Agreement with Encompass Therapeutic Support Systems Adding New Surface Choice for Use with Hill-Rom Frames
3. Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems
4. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
5. Vocollect Healthcare Systems Names Michael French as Vice President of Customer Experience
6. Top Indian Cancer Hospital to Introduce Advanced Radiosurgery Treatments With Novalis Tx from Varian Medical Systems and BrainLAB
7. Air Methods Awarded $15 Million Contract From General Dynamics Land Systems
8. Samplify Systems Announces Availability of Worlds First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression
9. Varian Medical Systems Schedules Fiscal Year End Review in New York
10. American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference
11. XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...wire/ -- Recent news reports have highlighted the ...hat physicians meet high standards in their chosen... of Medical Specialties (ABMS), which coordinates ...to develop and implement educational and professio... of physician specialists. Certification by an AB...
(Date:7/2/2009)...wire/ -- Pro-life forces won an important battle y...ld a state law regulating that abortion centers mu... RU-486 (also known as the "abortion pill") in ord... , , The ruling came in Rogers v. Planned Pare...04 law requiring that those administering RU-486 c...
(Date:7/2/2009)...honored in Washington, D.C. , , ARLINGTON, Tex...th Resources has received the Best Employers for ...ss Group on Health. , , (Logo: http://www.ne..., , The award recognizes the nation,s leading co...healthy workplace and for helping employees and th...
(Date:7/2/2009)... threat, expert says , , THURSDAY, July... certain species of wildlife, which need to be pro... , "Cancer is one of the leading health concern...of human deaths. But we now understand that cancer...hor Denise McAloose, chief pathologist for the Wil...
Breaking Medicine News(10 mins):Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Cancer Endangers Some Wildlife Species 2
... have discovered a naturally occurring hormone tha...%. Mice lacking the gene for klotho began showing ...e and die after // about two months when compared ...is has indeed opened up new avenues into improving...
... report published in the latest edition of The Lan...n treating adults with malaria than the common dru...r the treatment // of severe malaria throughout Af... But even with prompt administration of the drug i...
...ug 26 . Japanese encephalitis deaths continue to r...ed 220 in less than a month. // Dr.T.N.Dhole from...i Post Graduate Institute of Medical Sciences bla... spread of the killer brain fever, which had been ...
...n country of Uganda reports that all the efforts t...ing. The report on this topic was reported in this...nosoma brucei rhodesiense sleeping // sickness in ...lt of the movement of the livestock reservoir of t...
Other Medicine News:Health News:Encephalitis Deaths Cross 220 in Uttar Pradesh 2
(Date:6/29/2009)...Study Seeks to Assess RSV Burden in Outpatient Set...ment to Pediatric Research , , GAITHERSBURG, ...o advance its commitment to pediatric research wit...prospective study designed to assess the burden of...nfants 32-to-35 weeks gestational age (GA) in outp...
(Date:6/29/2009)...or abdominal surgery patients achieved primary and...June 29 AcelRx Pharmaceuticals, In...d Phase 2 clinical study evaluating the safety and...r the management of acute post-operative pain in p...ization. Compared to placebo, patients receiving A...
(Date:6/29/2009)...TON, England, June 29 Vantia Thera...oping novel, small molecule drugs,targeting large...results from,a Phase IIa clinical trial of its le...e trial showed that oral VA106483 was successful i...etic effect in patients, as determined by,increas...
(Date:6/28/2009)...E DO CORONADO, Portugal, June 29 D...at add-on treatment with the novel,once-daily an... ESL) resulted,in a marked and sustained decrease... Results from the one-year extension of a pivot...resented at the International Congress for Epileps...
Breaking Medicine Technology:MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 1Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 2Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 24144 3HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 1HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 2HistoRx Names Bill Sullivan Senior Vice President Diagnostic Operations 6613 3BioMS Medicals relapsing remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 6610 1BioMS Medicals relapsing remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 6610 2Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 1Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 2Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 3Cynosure Introduces Affirm CO2 28TM 29 Workstation for Advanced Ablative Therapy 6607 4
...IRE)--Mar 6, 2007 - POZEN Inc.,(NASDAQ: POZN), tod...n" PA 325 proof-of-concept study conducted during ...ormulation of 325mg of,aspirin surrounded by a 20m... proton pump inhibitor., The PA 325, 28 day study,...f 50. Each subject was treated with either once a ...
...LL, N.C., US, March 06, 2007,/PRNewswire/ -- AOP O...io, Inc. ("Lantibio") today announced positive fin...linded Phase II clinical,study of Moli1901, an exp.... Moli1901 is being developed by AOP Orphan in,Eur...ent with,Lantibio. The study, performed at multipl...
Other Medicine Technology:POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4
...n (MST) is a surgical technique designed to treat ...rea that cannot be surgically resected without cau... technique, fine parallel cuts are made in the cor... seizure discharge without compromising the vertic...
...s were developed to reproducibly and accurately cr... double bundle PCL reconstruction. The guides simp...teromedial femoral tunnel sockets drilled endoscop...erolateral tunnel placement a guide can be used ei...
...t offers surgeons an alternative to traditional ar...hammertoe deformity. The prosthesis is constructed...ed for the proximal interphalangeal joints of digi...atomic hinge design similar to that used in digita...
The primary objective of the BioPro Toe implant is to provide a durable arthroplasty that will relieve pain and restore motion while leaving the biomechanical arrangement of the foot undisturbed. The
Medicine Products: